Sponsored by GSK
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.